Publication Topic

Heintz MM, Buerger AN, Haws LC, Cullen JM, East AW, Thompson CM. 2025. Comparison of phenotypic and transcriptomic profiles between HFPO-DA and prototypical PPARα, PPARγ, and cytotoxic agents in wild-type and Pparα-null mouse livers. Toxicol Sci 206(1):183-201; doi: 10.1093/toxsci/kfaf049. PMID: 40216583.

Heintz MM, Buerger AN, Haws LC, East AW, Cullen JM, Thompson CM. Comparison of phenotypic and transcriptomic profiles between HFPO-DA and prototypical PPARα, PPARγ, and cytotoxic agents in wild-type and PPARα knockout mice. Abstract 3972, Society of Toxicology 64^th Annual Meeting, Orlando, FL, March 2025

Zilber D, Messier KP, House J, Parham F, Auerbach SS, Wheeler MW. 2025. Bayesian gene set benchmark dose estimation for “omic” responses. Bioinformatics 41(1):btaf008; doi: 10.1093/bioinformatics/btaf008. PMCID: PMC11783320.

Pennell ML, Wheeler MW, Auerbach SS. 2024. A hierarchical constrained density regression model for predicting cluster‐level dose‐response. Environmetrics 35(7):e2880; doi: 10.1002/env.2880.

O’Brien J, Mitchell C, Auerbach S, Doonan L, Ewald J, Everett L, Faranda A, Johnson K, Reardon A, Rooney J., Wheeler MW, et al. 2024. Bioinformatic workflows for deriving transcriptomic points of departure: Current status, data gaps, and research priorities. Toxicol Sci 203(2):147-159; doi: 10.1093/toxsci/kfae145. PMCID: PMC11775421.

Klaren WD, Heintz MM, East AW, Thompson CM, Haws LC. In vitro transcriptomic analyses informing the mode of action of HFPO-DA (GenX) in the liver. Poster presented at Society of Toxicology Annual Meeting, Nashville, TN, March 2023.

Heintz MM, Chappell GA, Thompson CM, Haws LC. 2022. Evaluation of transcriptomic responses in livers of mice exposed to the short-chain PFAS compound HFPO-DA. Front Toxicol 4(Jun 27):937168; doi: 10.3389/ftox.2022.937168. PMID: 35832492.

Chappell GA, Wolf JC, Thompson CM. 2021. Crypt and villus transcriptomic responses in mouse small intestine following oral exposure to hexavalent chromium. Toxicol Sci 186(1):43-57; doi: 10.1093/toxsci/kfab152. PMID: 34935971.

Chappell GA, Heintz MM, Haws LC. 2021. Transcriptomic analyses of livers from mice exposed to 1,4-dioxane for up to 90 days to assess potential mode(s) of action underlying liver tumor development. Curr Res Toxicol 2:30–41; doi: 10.1016/j.crtox.2021.01.003.

Chappell GA, Thompson CM, Wolf J, Cullen J, Haws LC. Transcriptomic responses in livers of GenX-treated mice demonstrate up-regulation of PPAR signaling and related pathways. Environmental Mutagenesis and Genomics Society, Washington, DC, September 2019.

Chappell GA, Rager JE, Wolf JC, Babic M, LeBlanc KJ, Ring CL, Harris MA, Thompson C. Similarities in the transcriptomic signatures in the duodenum of mice exposed to hexavalent chromium, captan, or folpet inform the mechanisms of chemical-induced mouse small intestine cancer. Presentation at Society of Toxicology 58th Annual Meeting, Baltimore, MD, March 2019.

Rager JE, Ring CL, Fry RC, Suh M, Proctor DM, Haws L, Harris MA, Thompson CM. 2017. High-throughput screening data interpretation in the context of in vivo transcriptomic responses to oral Cr(VI) exposure. Toxicol Sci 158(1):199–212; doi: 10.1093/toxsci/kfx085.

Rager JE, Thompson CM, Ring C, Fry RC, Harris MA. Integration of transcriptomics and high-throughput screening predictions with robust in vivo data to inform hexavalent chromium mode of action. Poster presented at Society of Toxicology 56th Annual Meeting, Baltimore, MD, March 2017.

Thompson CM, Rager JE, Suh M, Ring CL, Proctor DM, Haws LC, Fry RC, Harris MA. 2016. Transcriptomic responses in the oral cavity of F344 rats and B6C3F1 mice following exposure to Cr(VI): Implications for risk assessment. Environ Molec Mutagen 57(9):706-716; doi: 10.1002/em.22064.

Peters JM, Aoyama T, Burns AM, Gonzalez FJ. 2003. Bezafibrate is a dual ligand for PPARalpha and PPARbeta: Studies using null mice. Biochim Biophys Acta 1632(1-3):80-89; doi: 10.1016/s1388-1981(03)00065-9. PMID: 12782154.